December 8, 2020
Patients in South Africa to Access Six-Month, All-Oral Treatment for Highly Drug-Resistant Tuberculosis
October 30, 2020
TB Alliance is Honored to Accept the Prix Galien Award for Best Pharmaceutical Agent
October 23, 2020
TB Alliance with the Support of the Republic of Korea Announce Initiative to Broaden Adoption and Scale Up of New Treatments for Drug-Resistant Tuberculosis (TB)
LIFT-TB to increase treatment completion rates for drug-resistant TB, focusing on seven high-burden Southeast and Central Asian countries that shoulder about 1 in 5 TB cases October 14, 2020
With Progress against TB in Jeopardy, New and Improved Tools Are More Urgent than Ever
August 4, 2020
Dr. Mel Spigelman Named in Fast Company’s Annual List of the Most Creative People in Business
August 3, 2020
TB Alliance Announces European Commission Authorisation of New Treatment for Highly Drug-Resistant Tuberculosis
Pretomanid, developed by the non-profit TB Alliance, has received EU marketing authorisation in combination regimen with bedaquiline and linezolid in adults with XDR-TB or treatment-intolerant/non-responsive MDR-TB July 22, 2020